Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (NASDAQ: OM) is a medical technology company focused on transforming dialysis with its Tablo Hemodialysis System, and its news flow reflects both business performance and developments in kidney care. Company press releases regularly describe Outset as pioneering a first-of-its-kind technology designed to reduce the cost and complexity of dialysis across hospital and home settings.
News updates for OM commonly include quarterly financial results, where Outset reports product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and cash balances. These releases may also include revised or updated annual revenue guidance and commentary on progress toward financial objectives.
Investors and clinicians following Outset Medical can also expect clinical and research news. The company has highlighted data from large numbers of Tablo treatments across hundreds of facilities, as well as multi-year results from hospitals that have insourced dialysis service lines using Tablo. Such announcements focus on clinical outcomes, operational metrics, and the implications of insourced dialysis models for acute-care facilities.
Outset’s news stream further covers strategic and corporate developments, such as board appointments, the creation of clinical leadership roles, and collaborations with dialysis providers to expand access to home hemodialysis using Tablo. The company also announces presentations at major healthcare and investor conferences, where management discusses its technology, business strategy, and financial performance.
This OM news page aggregates these releases so readers can follow Outset Medical’s earnings reports, clinical evidence updates, collaborations, and corporate milestones in one place.
Outset Medical, Inc. (NASDAQ: OM), a pioneering medical technology firm, announced its participation in two upcoming investor conferences. The Bank of America Securities 2023 Health Care Conference is scheduled for May 9, 2023, at 1:40 PM PT, while the RBC Capital Markets Global Healthcare Conference will take place on May 17, 2023, at 5:00 AM PT. Live and archived webcasts of these events will be accessible via the Outset Investors' website.
Outset's flagship product, the Tablo Hemodialysis System, aims to streamline dialysis, making it more accessible and efficient for patients and providers. This innovative system integrates water purification and on-demand dialysate production, positioning it as a versatile solution for dialysis care.
Outset Medical, Inc. (NASDAQ: OM) has released five new abstracts at the National Kidney Foundation Spring Clinical Meetings highlighting innovations in home hemodialysis (HHD) and gender biases in nephrology. The studies demonstrate clinical and financial benefits of HHD, particularly in Hawaii, where Tablo was implemented effectively under challenging conditions. Key findings include a potential savings of
Outset Medical, Inc. (NASDAQ: OM) announced plans to release its financial results for Q1 2023 on May 3, 2023, after market close. CEO Leslie Trigg and CFO Nabeel Ahmed will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. The company focuses on revolutionizing dialysis with its Tablo® Hemodialysis System, which simplifies operational processes and enhances patient care. The system integrates water purification and dialysate production, serving as a mobile dialysis clinic. Interested parties can register online for the call and access a live or archived webcast on the Outset Investors page.
Outset Medical, Inc. (Nasdaq: OM), a leader in medical technology, announces participation in a fireside chat at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023, at 9:50 a.m. PT / 12:50 p.m. ET. The event will be available via live and archived webcast on the Outset website.
Outset is known for its innovative Tablo Hemodialysis System, which simplifies dialysis by allowing for its use in various settings, from hospitals to homes. This FDA-cleared technology enhances patient care and operational efficiency, integrating water purification and on-demand dialysate production.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
